1. Home
  2. ZD vs NTLA Comparison

ZD vs NTLA Comparison

Compare ZD & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ziff Davis Inc.

ZD

Ziff Davis Inc.

HOLD

Current Price

$43.50

Market Cap

1.7B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.49

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZD
NTLA
Founded
1995
2014
Country
United States
United States
Employees
3900
377
Industry
Advertising
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
1999
2016

Fundamental Metrics

Financial Performance
Metric
ZD
NTLA
Price
$43.50
$13.49
Analyst Decision
Hold
Buy
Analyst Count
7
20
Target Price
$39.71
$20.45
AVG Volume (30 Days)
729.4K
3.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
1.15
N/A
Revenue
$1,364,028,000.00
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.16
$62.75
P/E Ratio
$38.49
N/A
Revenue Growth
N/A
16.92
52 Week Low
$22.45
$6.73
52 Week High
$50.55
$28.24

Technical Indicators

Market Signals
Indicator
ZD
NTLA
Relative Strength Index (RSI) 60.76 51.57
Support Level $34.96 $12.55
Resistance Level $45.26 $14.32
Average True Range (ATR) 1.98 0.76
MACD -0.18 0.07
Stochastic Oscillator 60.93 60.80

Price Performance

Historical Comparison
ZD
NTLA

About ZD Ziff Davis Inc.

Ziff Davis Inc is a digital media and internet company operating a portfolio of brands across technology, shopping, gaming and entertainment, health and wellness, connectivity, and cybersecurity. The company has five reportable segments. The Technology & Shopping segment generates revenue from advertising and commerce content. The Gaming & Entertainment segment provides content, subscriptions, and digital storefront services. The Health & Wellness segment offers digital tools and content for health management. The Connectivity segment provides data and analytics solutions for network performance. The Cybersecurity & Martech segment delivers cloud-based software for security and marketing. It generates the majority of its revenue from the Health & Wellness segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: